Related Experiment Video
Updated: Jan 10, 2026
08:24
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
Published on: November 25, 2022
2.6K
Small molecule inhibitors targeting alpha-synuclein aggregation: Progress and future outlook.
Ishfaq Bashir Hajam1, Ishfaq Ahmad Ahanger1, Umar Rasool1
1Department of Clinical Biochemistry, University of Kashmir, Srinagar, Jammu and Kashmir, India.
Advances in Protein Chemistry and Structural Biology
|November 27, 2025
Summary
Small molecule inhibitors targeting alpha-synuclein (α-syn) aggregation show promise for Parkinson's disease (PD) treatment. This review explores their development, clinical trials, and future potential for disease modification.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Parkinson's disease (PD) is characterized by alpha-synuclein (α-syn) aggregation, causing neuronal dysfunction.
- Targeting α-syn aggregation is a key therapeutic strategy for PD.
Purpose of the Study:
- To review the progress in developing small molecule inhibitors for α-syn aggregation.
- To update on the clinical trial status of these inhibitors and discuss emerging strategies.
Main Methods:
- Literature review of small molecule inhibitors targeting α-syn aggregation.
- Analysis of mechanisms of α-syn misfolding and aggregation.
- Overview of clinical trial data and emerging therapeutic approaches.
Main Results:
- Several small molecule inhibitors are in development to prevent or reverse α-syn aggregation.
- Clinical trials are ongoing, with some showing promising results.
- Emerging strategies like combination therapies and chaperone therapeutics may enhance efficacy.
Conclusions:
- Small molecule inhibitors represent a promising avenue for disease-modifying treatments in PD.
- Further research and clinical trials are essential to realize their full therapeutic potential.
- Combination therapies and novel approaches could improve treatment outcomes for Parkinson's disease.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
03:03Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K
02:30siRNA - Small Interfering RNAs
18.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.3K
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K